TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with peritoneal metastasis from appendix, colon, small bowel, endometrium, ovary or any other GI or Gyn primary tumor~* Patients should be eligible for and consent to surgery with the intention of performing CRS / HIPEC at Penn State Hershey Medical Center. Eligibility for CRS/HIPEC is a clinical determination based on a combination of factors including radiographic extent of disease, tumor histology and medical fitness for surgery~* Subjects who are explored but found to be unresectable will be included.~* Male or female.~* Patients should be age 18 or above.~* Surgery is planned for not less than 6 weeks and no more than 10 weeks from consultation~Exclusion Criteria:~* Patients who do not consent to surgery.~* Patients who require urgent surgery, sooner than 6 weeks~* Patients receiving neoadjuvant chemotherapy, with no surgical date planned before 10 weeks from consultation. These patients can be enrolled at the time of the follow-up visit, as long as they meet above criteria~* Patients not fluent in English~* Pregnant women~* Prisoners~* Patients with Cognitive Impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exercise Group (Type: EXPERIMENTAL): Exercise Program Subjects randomized to the intervention arm should have 6 weeks of home exercise prior to surgery, with a minimum of 5 weeks and not more than 7 weeks. The program will begin with an exercise consultation appointment with a certified fitness professional. During this consultation participants will receive an exercise manual for individualized home-based exercise and a practical introduction by an exercise and cancer specialist. PowerBlock adjustable dumbbells will be used for resistance training exercises and walking or jogging will be the primary type of aerobic training. The current program design was developed and successfully used with women with breast cancer. Thus, some components may need modification for this group of patients with advanced GI cancer.
- Education Group (Type: ACTIVE_COMPARATOR): Subjects randomized to the control arm will receive education and a handbook on the benefits of exercise and will be encouraged to have adequate protein in their diet and provided with the list of high protein foods and nutritional information. These subjects will undergo the same assessments as the intervention arm at all time points. Control subjects will be offered a 6-week home exercise program 3 months after CRS/HIPEC. Results and outcomes will not be recorded.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endometrial Injury Versus Luteal Phase Support in Intrauterine Insemination Cycles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients are undergone intrauterine insemination with gonadotropin stimulation~* Bilateral patent fallopian tubes revealed by hysterosalpingography or laparoscopy~* After semen preparation for intrauterine insemination, total progressive sperm count \> 5 million~Exclusion Criteria:~* endocrin or metabolic disorders,~* uterine factor,~* pelvic inflammatory disease,~* women with basal follicle-stimulating hormone (FSH) level \>15 IU/mL,~* body mass index (BMI) ≥ 35 kg/m2,~* age ≥ 40 and \< 18 years,

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Endometrial Injury (Type: ACTIVE_COMPARATOR): Endometrial injury in luteal phase of preceding IUI cycle
- Luteal Phase Support (Type: ACTIVE_COMPARATOR): Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
- Control group (Type: NO_INTERVENTION): Only IUI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women aged over 18 years old;~* Who received in the last 7 days the diagnosis of metastatic incurable bladder, prostate, kidney, colorectal or sarcoma cancer (including recurrence) during the announcement visit;~* Whose life expectancy is estimated ≥ 6 months by their treating oncologist;~* Who have a WHO performance score \< 3 (to be coherent with the life expectancy);~* Who have an albumin level \> 30g/liter (patients with an acceptable state of nutrition);~* Who gave their signed consent to participate in the study;~* Who are covered by a social insurance.~Exclusion Criteria:~* Patients diagnosed with cerebral metastases;~* Patients with locally advanced cancer without metastases;~* Patients with an advanced or metastatic cancer amenable to curative intent treatment;~* Patients suffering from a psychological vulnerability that might alter their reasoning or judgment capacities;~* Patients with a psychological or physical incapacity to answer the questionnaires, attested by the medical staff;~* Patients under custodial sentence or under tutelage or protection of vulnerable adults

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental arm (Type: EXPERIMENTAL): In the experimental group, participants will perform vagal breathing (VB), followed by the MSI, followed again by VB. The VB component will guide participants how to perform deep slow vagal breathing by inhaling and counting 1-5, holding their breath and counting 1-2, and exhaling and counting 1-5, during 2-5 minutes. The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).
- Control Arm (Type: OTHER): Participants in the control group will receive support and attention (usual care) and will be invited to recall announcement of the incurable disease progression. More precisely, they will be invited to express their associated thoughts and feelings, being free to talk about their experience, and the psychologist will react with empathy and support.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial of Surfactant Administration by Laryngeal Mask Airway (LMA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Birthweight \> 1200 grams~* Chronologic age \< 72 hours.~* Diagnosis of RDS by clinical and radiographic criteria.~* Treated with nasal CPAP and supplemental oxygen \> 30% and not requiring \> 60% FiO2 for longer than 30 minutes to maintain SaO2 88-95%.~* Parental consent.~Exclusion Criteria:~* Birthweight \< 1200 gms.~* Diagnosis other than RDS (e.g., meconium aspiration syndrome).~* Babies who require or have already had endotracheal intubation.~* Babies with congenital anomalies or conditions thought by the attending physician to contribute to respiratory symptoms and/or to restrict adequate spontaneous breathing (e.g., congenital heart disease, obtundation from maternal drugs, certain airway malformations, diaphragmatic hernia).

- Gender: ALL
- Minimum Age: None
- Maximum Age: 72 Hours
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Surfactant by LMA
- 2 (Type: OTHER): Standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Self Management Education Asthma

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
No eligibility criteria

- Gender: MALE
- Minimum Age: 0 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Previously untreated patients with DLBCL of the breast.~* Patients must have CD20 positive tumors.~* Stage IE or IIE.~* Must have at least one objective measurable or evaluable disease. Baseline measurements and evaluations must be obtained within 4 weeks of registration to the study.~* Patients must not have historical or radiographic evidence of CNS metastasis including previously treated, resected or asymptomatic brain lesions or leptomeningeal involvement.~* Patients must have an ECOG performance status 0-2.~* Patients must have adequate organ function as evidenced by the following laboratory studies (within 2 weeks prior to registration):~  * Creatinine Clearance \>= 50 ml/min~ * Total bilirubin \<= 2.0 mg/dl and AST \<= 2 x upper limit of normal. If documented hepatic involvement with lymphoma, total bilirubin can be \<= 3 x \*ULN, and AST \<= 5 x ULN.~ * Absolute neutrophil count \>= 1500/mm3 and platelet count \>= 100,000/mm3. If documented bone marrow involvement with lymphoma, absolute neutrophil count \>= 500/mm\^3 and platelet count \>= 50,000/mm\^3.~* Patients must be age \>= 18 years.~* Women must not be pregnant or breast feeding due to potential harmful effects to the fetus/baby. Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of contraception.~* Patients must not have an active infection requiring parental antibiotics.~* Patients with known HIV infection are excluded.~* Patients must have a normal left ventricular ejection fraction to be eligible.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of rubeosis iridis in patients with retinal ischemia.~2. Patients must be 18 years of age or older to receive treatment.~3. Visual acuity of 20/30 to 20/320 Study Eye on the ETDRS visual acuity chart.~4. Visual acuity of 20/800 or better Fellow Eye on the ETDRS visual acuity chart.~Exclusion Criteria:~1. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.~2. Patients who have undergone intraocular surgery within last 2 months.~3. Patient participating in any other investigational drug study.~4. Use of an investigational drug or treatment related or unrelated to their condition within 30 days prior to receipt of study medication.~5. Inability to obtain photographs to document CNV (including difficulty with venous access.~6. Patient with significant liver disease or uremia.~7. Patient with known adverse reaction to fluorescein and indocyanine green or iodine.~8. Patient has a history of any medical condition which would preclude scheduled visits or completion of study.~9. Patient has had insertion of scleral buckle in the study eye.~10. Patient has received radiation treatment.~11. Patient is pregnant or nursing.~12. Patient is on intravenous or subcutaneous anticoagulant therapy, or is on oral anticoagulant therapy (with the exception of aspirin and antiplatelet therapy) and cannot take a 5-day interruption in therapy prior to each depot or sham administration.~13. Patient has evidence of scleral thinning seen at the time of external eye exam or at the time of depot or sham administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Patient :~Inclusion Criteria:~* To be able to identify a principal caregiver via a specific questionnaire (if the patient is unable to identify himself his caregiver due to the disease, a self-designation form as a principal caregiver will be allow and propose)~* to accept to complete the questionnaire to designate the principal caregiver;~* To live in either Burgundy-Franche-Comte county;~* have been recently diagnosed at hospital or in private-sector for the following diseases: Local or metastatic cancer diagnosed less than 6 month (breast cancer-hormone sensitive- in first line chemotherapy treatment, hormone-sensitive prostate cancer or in metastatic recurrence after 3 years of remission, considered as a new case, colorectal cancer in first line chemotherapy treatment), a neuro-degenerative disease (Parkinson disease diagnosed less than 7 years, Alzheimer disease and similar diseases diagnosed less than 12 months and /or with a Mini Mental State Examination (MMSE)\<24 and \>10 (performed less than 3 mois)), Age-related Macular Degeneration,( geographic atrophy or neovascular, diagnosed less than 12 month with an acuity range between 2 and 6/10e, be at least 65 years old and have received less than 3 sessions of intravitreal injections (IVT)), cardiac disease (heart failure diagnosed less than 3 months), neuro-vascular disease (ischemic or hemorrhagic stroke with clinical evidence of post stroke lesions upper than 24 hours, diagnosed less than 6 months and with a Rankin's score inferior or equal to 2).~Exclusion Criteria:~* previously diagnosed with another targeted disease and/or living in retirement home could not be included~Caregiver~Inclusion Criteria:~* to be a member of the patient's social environment (family, friend and neighbor);~* to be identify by the patient as the principal caregiver based on the designation questionnaire or to have complete the self-designation form as a principal caregiver;~* ≥ 18 years old;~* not be an employee of a healthcare organization;~* living in Burgundy-Franche-Comte;~* to be able to complete questionnaires,~Exclusion Criteria:~- to be under guardianship, curatorship or under the protection of justice

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Interventional arm (Type: EXPERIMENTAL): 'Support provided by social worker'
- Non-interventional arm (Type: OTHER): 'Information booklet receipt'

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Tibolone and Escitalopram in Perimenopausal Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Females who are currently physically well and between 45 and 55 years of age~* Current DSM-IV diagnosis of depression disorder~* Able to give informed consent~* Perimenopausal as determined by symptom profile on the Stages of Reproductive Aging Workshop and gonadal hormonal profile~Exclusion Criteria:~* Known abnormalities in the hypothalamic-pituitary gonadal axis, thyroid dysfunction, central nervous system tumours, active or past history of a venous thromboembolic event, breast pathology, undiagnosed vaginal bleeding or abnormal Pap smear results in the previous 2 years.~* Patients with any significant unstable medical illness such as epilepsy and diabetes or known active cardiac, renal or liver disease; or the presence of illness causing immobilisation.~* Patients receiving treatment for depression including antidepressant medications, electroconvulsive therapy (ECT) / Transcranial Magnetic Stimulation (TMS), formal psychotherapy or counselling, within the past 6 months~* Patients experiencing severe melancholia, neurovegetative symptoms or current suicidality necessitating acute hospitalisation or intensive psychiatric treatment.~* Patients with psychotic symptoms or past history of severe mental illness including schizophrenia, and bipolar disorder.~* Use of any form of estrogen, progestin or androgen as hormonal therapy, or antiandrogen including tibolone or use of phytoestrogen supplements as powder or tablet~* Pregnancy / Lactation~* Smoking cigarettes and other nicotine products.~* illicit drug use and more than 3 standard drinks per day

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Tibolone (Type: EXPERIMENTAL): Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial.
- Escitalopram (Type: ACTIVE_COMPARATOR): 10mg of escitalopram will be taken by participants daily for the duration of the 12 week trial period.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo arm containing sweetener has been approved and will be used as placebo arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acetabular Bone Vascularity in Metal-on-Metal Revisions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients being revised for an aseptic metal on metal acetabular revision.~* Patient is greater than one year postoperative.~* Patient has had cobalt and chromium metal ion levels tested within 6 months of the planned revision surgery.~* Understands the local language and is willing and able to follow the requirements of the protocol.~* Understands the informed consent and signs the institutional review board or independent ethics committee (IRB/IEC) approved informed consent form.~Exclusion Criteria:~* History of infection~* Evidence of current substance or alcohol abuse~* Being treated with radiation, chemotherapy, immunosupression, or chronic steroid therapy (prednisone use up to 5 mg/qd or its equivalent is allowed)~* Is a prisoner

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metal-on-Metal Revision (Type: None): Patients who have a failed metal on metal total hip implant and are presenting for revision surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Brachiocephalic Arteriovenous Fistulae: Two Different Techniques of Bloodless Surgery and Their Effect on Fistula Stenosis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mentally competent~* Written informed consent~* Age 18 years and older~* Indication for brachiocephalic AVF in HagaZiekenhuis~* Patient is able to complete the follow-up evaluation~Exclusion Criteria:~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vascular clamps (Type: NO_INTERVENTION): Patients randomized to the use of vascular clamps to obtain a bloodless field during arteriovenous fistula surgery (standard protocol).
- Tourniquet (Type: EXPERIMENTAL): Patients randomized to the use of a tourniquet to obtain a bloodless field during arteriovenous fistula surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues